1048 related articles for article (PubMed ID: 19538338)
1. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease.
Olcese JM; Cao C; Mori T; Mamcarz MB; Maxwell A; Runfeldt MJ; Wang L; Zhang C; Lin X; Zhang G; Arendash GW
J Pineal Res; 2009 Aug; 47(1):82-96. PubMed ID: 19538338
[TBL] [Abstract][Full Text] [Related]
2. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.
Arendash GW; Schleif W; Rezai-Zadeh K; Jackson EK; Zacharia LC; Cracchiolo JR; Shippy D; Tan J
Neuroscience; 2006 Nov; 142(4):941-52. PubMed ID: 16938404
[TBL] [Abstract][Full Text] [Related]
3. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease.
Feng Z; Chang Y; Cheng Y; Zhang BL; Qu ZW; Qin C; Zhang JT
J Pineal Res; 2004 Sep; 37(2):129-36. PubMed ID: 15298672
[TBL] [Abstract][Full Text] [Related]
4. A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice.
Arendash GW; Jensen MT; Salem N; Hussein N; Cracchiolo J; Dickson A; Leighty R; Potter H
Neuroscience; 2007 Oct; 149(2):286-302. PubMed ID: 17904756
[TBL] [Abstract][Full Text] [Related]
5. Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging.
Jensen MT; Mottin MD; Cracchiolo JR; Leighty RE; Arendash GW
Neuroscience; 2005; 130(3):667-84. PubMed ID: 15590151
[TBL] [Abstract][Full Text] [Related]
6. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease.
Boissonneault V; Filali M; Lessard M; Relton J; Wong G; Rivest S
Brain; 2009 Apr; 132(Pt 4):1078-92. PubMed ID: 19151372
[TBL] [Abstract][Full Text] [Related]
7. Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice.
Rezai-Zadeh K; Arendash GW; Hou H; Fernandez F; Jensen M; Runfeldt M; Shytle RD; Tan J
Brain Res; 2008 Jun; 1214():177-87. PubMed ID: 18457818
[TBL] [Abstract][Full Text] [Related]
8. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice.
Trinchese F; Liu S; Battaglia F; Walter S; Mathews PM; Arancio O
Ann Neurol; 2004 Jun; 55(6):801-14. PubMed ID: 15174014
[TBL] [Abstract][Full Text] [Related]
9. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice.
Arendash GW; Mori T; Cao C; Mamcarz M; Runfeldt M; Dickson A; Rezai-Zadeh K; Tane J; Citron BA; Lin X; Echeverria V; Potter H
J Alzheimers Dis; 2009; 17(3):661-80. PubMed ID: 19581722
[TBL] [Abstract][Full Text] [Related]
10. Use of multimetric statistical analysis to characterize and discriminate between the performance of four Alzheimer's transgenic mouse lines differing in Abeta deposition.
Leighty RE; Nilsson LN; Potter H; Costa DA; Low MA; Bales KR; Paul SM; Arendash GW
Behav Brain Res; 2004 Aug; 153(1):107-21. PubMed ID: 15219712
[TBL] [Abstract][Full Text] [Related]
11. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
Zhang W; Hao J; Liu R; Zhang Z; Lei G; Su C; Miao J; Li Z
Behav Brain Res; 2011 Sep; 222(2):342-50. PubMed ID: 21513747
[TBL] [Abstract][Full Text] [Related]
12. Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein.
Lee KW; Lee SH; Kim H; Song JS; Yang SD; Paik SG; Han PL
J Neurosci Res; 2004 May; 76(4):572-80. PubMed ID: 15114629
[TBL] [Abstract][Full Text] [Related]
13. Differential susceptibility following beta-amyloid peptide-(1-40) administration in C57BL/6 and Swiss albino mice: Evidence for a dissociation between cognitive deficits and the glutathione system response.
Prediger RD; Franco JL; Pandolfo P; Medeiros R; Duarte FS; Di Giunta G; Figueiredo CP; Farina M; Calixto JB; Takahashi RN; Dafre AL
Behav Brain Res; 2007 Feb; 177(2):205-13. PubMed ID: 17194489
[TBL] [Abstract][Full Text] [Related]
14. Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer's disease.
Chavant F; Deguil J; Pain S; Ingrand I; Milin S; Fauconneau B; Pérault-Pochat MC; Lafay-Chebassier C
J Pharmacol Exp Ther; 2010 Feb; 332(2):505-14. PubMed ID: 19889791
[TBL] [Abstract][Full Text] [Related]
15. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.
Melnikova T; Savonenko A; Wang Q; Liang X; Hand T; Wu L; Kaufmann WE; Vehmas A; Andreasson KI
Neuroscience; 2006 Sep; 141(3):1149-62. PubMed ID: 16753269
[TBL] [Abstract][Full Text] [Related]
16. Genetic deletion or antagonism of kinin B(1) and B(2) receptors improves cognitive deficits in a mouse model of Alzheimer's disease.
Prediger RD; Medeiros R; Pandolfo P; Duarte FS; Passos GF; Pesquero JB; Campos MM; Calixto JB; Takahashi RN
Neuroscience; 2008 Feb; 151(3):631-43. PubMed ID: 18191900
[TBL] [Abstract][Full Text] [Related]
17. Beta-amyloid pathology in the entorhinal cortex of rats induces memory deficits: implications for Alzheimer's disease.
Sipos E; Kurunczi A; Kasza A; Horváth J; Felszeghy K; Laroche S; Toldi J; Párducz A; Penke B; Penke Z
Neuroscience; 2007 Jun; 147(1):28-36. PubMed ID: 17499931
[TBL] [Abstract][Full Text] [Related]
18. A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment.
Leon WC; Canneva F; Partridge V; Allard S; Ferretti MT; DeWilde A; Vercauteren F; Atifeh R; Ducatenzeiler A; Klein W; Szyf M; Alhonen L; Cuello AC
J Alzheimers Dis; 2010; 20(1):113-26. PubMed ID: 20164597
[TBL] [Abstract][Full Text] [Related]
19. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities.
Savonenko A; Xu GM; Melnikova T; Morton JL; Gonzales V; Wong MP; Price DL; Tang F; Markowska AL; Borchelt DR
Neurobiol Dis; 2005 Apr; 18(3):602-17. PubMed ID: 15755686
[TBL] [Abstract][Full Text] [Related]
20. Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain.
Arendash GW; Lewis J; Leighty RE; McGowan E; Cracchiolo JR; Hutton M; Garcia MF
Brain Res; 2004 Jun; 1012(1-2):29-41. PubMed ID: 15158158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
